Alterity Therapeutics Limited
May 05, 2025 - by Joey Ramson
$ATHE is up today and leading the Prism MarketView GlobalHealth index after the FDA granted Fast Track designation for its lead candidate, ATH434, aimed at treating Multiple System Atrophy (MSA) – a condition currently without any approved therapies.
